GSK’s (GSK) “Underweight” Rating Reiterated at JPMorgan Chase & Co.

GSK (LON:GSK)‘s stock had its “underweight” rating reissued by equities research analysts at JPMorgan Chase & Co. in a note issued to investors on Friday, MarketBeat.com reports.

Separately, Berenberg Bank decreased their price target on shares of GSK from GBX 1,820 ($23.56) to GBX 1,600 ($20.71) and set a “buy” rating on the stock in a research note on Friday, November 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($23.37).

GSK Trading Up 0.6 %

Shares of LON:GSK opened at GBX 1,486.08 ($19.23) on Friday. The stock has a market cap of £60.30 billion, a PE ratio of 24.01, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK has a 12-month low of GBX 1,282.50 ($16.60) and a 12-month high of GBX 1,823.50 ($23.60). The business has a 50 day moving average of GBX 1,456.03 and a 200-day moving average of GBX 1,431.41.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities research analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insider Activity

In other news, insider Wendy Becker bought 536 shares of the company’s stock in a transaction dated Thursday, March 20th. The stock was bought at an average cost of GBX 1,515 ($19.61) per share, for a total transaction of £8,120.40 ($10,510.48). Also, insider Emma Walmsley sold 120,653 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($18.81), for a total transaction of £1,753,088.09 ($2,269,075.96). Corporate insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.